OncoMatch/Clinical Trials/NCT04209868

Preoperative Paravertebral Block in Cancer Surgery of the Lung

Is NCT04209868 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including Levo-Bupivacaine Hydrochloride (HCl) 0.5 % in 20mL and 0.9% Sodium Chloride 20mL for thoracic neoplasm.

Phase 2/3RecruitingGuy's and St Thomas' NHS Foundation TrustNCT04209868Data as of May 2026

Treatment: Levo-Bupivacaine Hydrochloride (HCl) 0.5 % in 20mL · 0.9% Sodium Chloride 20mL — The investigators aim to determine whether ultrasound-guided preemptive paravertebral blockade (PVB) local anaesthetic (pre-PVB LA), administered in addition to the post-operative PVB (post-PVB) local anaesthetic (LA) infusion, reduces acute postoperative pain, opioid requirement, chronic pain, and improves surgical recovery, in thoracoscopic surgery for lung cancer.

Check if I qualify

Extracted eligibility criteria

Performance status

ASA 1–3

Prior therapy

Cannot have received: lung surgery

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify